Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
S. Yusuf, S. Reddy, S. Ounpuu, S. Anand.
Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization.
Circulation, 104 (2001), pp. 2746-2753
[2.]
C.G.T.F. Santos-Gallego, J.J. Badimon.
The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results.
Clinical Lipidology, 6 (2011), pp. 181-208
[3.]
J.J. Badimon, C.G. Santos-Gallego, L. Badimon.
Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going?.
Rev Esp Cardiol, 63 (2010), pp. 20-35
[4.]
A.M. Giraldo, N. Loango, H. Castaño, P. Landázuri.
Actividad de la proteína transportadora de ésteres de colesterol Polimorfismos del gen en pacientes colombianos con enfermedad coronaria.
Rev Colomb Cardiol, 19 (2012), pp. 172-179
[5.]
C.G. Santos-Gallego, B. Ibanez, J.J. Badimon.
HDL-cholesterol: is it really good? Differences between apoA-I and HDL.
Biochem Pharmacol, 76 (2008), pp. 443-452
[6.]
A. Inazu, M.L. Brown, C.B. Hesler, L.B. Agellon, J. Koizumi, K. Takata, et al.
Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation.
N Engl J Med, 323 (1990), pp. 1234-1238
[7.]
P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J. Kastelein, M. Komajda, et al.
Effects of torcetrapib in patients at high risk for coronary events.
N Engl J Med, 357 (2007), pp. 2109-2122
[8.]
S.E. Nissen, J.C. Tardif, S.J. Nicholls, J.H. Revkin, C.L. Shear, W.T. Duggan, et al.
Effect of torcetrapib on the progression of coronary atherosclerosis.
N Engl J Med, 356 (2007), pp. 1304-1316
[9.]
J.J. Kastelein, S.I. van Leuven, L. Burgess, G.W. Evans, J.A. Kuivenhoven, P.J. Barter, et al.
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
N Engl J Med, 356 (2007), pp. 1620-1630
[10.]
M.L. Bots, F.L. Visseren, G.W. Evans, W.A. Riley, J.H. Revkin, C.H. Tegeler, et al.
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.
Lancet, 370 (2007), pp. 153-160
[11.]
R. Krishna, M.S. Anderson, A.J. Bergman, B. Jin, M. Fallon, J. Cote, et al.
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
Lancet, 370 (2007), pp. 1907-1914
[12.]
E.A. Stein, E.S. Stroes, G. Steiner, B.M. Buckley, A.M. Capponi, T. Burgess, et al.
Safety and tolerability of dalcetrapib.
Am J Cardiol, 104 (2009), pp. 82-91
[13.]
M.J. Chapman, W. Le Goff, M. Guerin, A. Kontush.
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
Eur Heart J, 31 (2010), pp. 149-164
[14.]
B. Lamarche, K.D. Uffelman, A. Carpentier, J.S. Cohn, G. Steiner, P.H. Barrett, G.F. Lewis.
Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men.
J Clin Invest, 103 (1999), pp. 1191-1199
[15.]
K.R. Marotti, C.K. Castle, T.P. Boyle, A.H. Lin, R.W. Murray, G.W. Melchior.
Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein.
Nature, 364 (1993), pp. 73-75
[16.]
W. de Haan, J. de Vries-van der Weij, J.W. van der Hoorn, T. Gautier, C.C. van der Hoogt, M. Westerterp, et al.
Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.
Circulation, 117 (2008), pp. 2515-2522
[17.]
T. Hayek, L. Masucci-Magoulas, X. Jiang, A. Walsh, E. Rubin, J.L. Breslow, et al.
Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene.
J Clin Invest, 96 (1995), pp. 2071-2074
[18.]
B. Foger, M. Chase, M.J. Amar, B.L. Vaisman, R.D. Shamburek, B. Paigen, et al.
Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice.
J Biol Chem, 274 (1999), pp. 36912-36920
[19.]
C. Harder, P. Lau, A. Meng, S.C. Whitman, R. McPherson.
Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice.
Arterioscler Thromb Vasc Biol, 27 (2007), pp. 858-864
[20.]
H. Okamoto, F. Yonemori, K. Wakitani, T. Minowa, K. Maeda, H. Shinkai.
A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits.
Nature, 406 (2000), pp. 203-207
[21.]
C.W. Rittershaus, D.P. Miller, L.J. Thomas, M.D. Picard, C.M. Honan, C.D. Emmett, et al.
Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis.
Arterioscler Thromb Vasc Biol, 20 (2000), pp. 2106-2112
[22.]
Z. Huang, A. Inazu, A. Nohara, T. Higashikata, H. Mabuchi.
Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia.
Clin Sci (Lond), 103 (2002), pp. 587-594
[23.]
J.A. Kuivenhoven, J.W. Jukema, A.H. Zwinderman, P. de Knijff, R. McPherson, A.V. Bruschke, The Regression Growth Evaluation Statin Study Group, et al.
The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis.
N Engl J Med, 338 (1998), pp. 86-93
[24.]
J.J. Regieli, J.W. Jukema, D.E. Grobbee, J.J. Kastelein, J.A. Kuivenhoven, A.H. Zwinderman, et al.
CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction.
Eur Heart J, 29 (2008), pp. 2792-2799
[25.]
R.S. Vasan, M.J. Pencina, S.J. Robins, J.P. Zachariah, G. Kaur, R.B. D’Agostino, et al.
Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community.
Circulation, 120 (2009), pp. 2414-2420
[26.]
K. Hirano, S. Yamashita, N. Nakajima, T. Arai, T. Maruyama, Y. Yoshida, et al.
Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity.
Arterioscler Thromb Vasc Biol, 17 (1997), pp. 1053-1059
[27.]
S. Zhong, D.S. Sharp, J.S. Grove, C. Bruce, K. Yano, J.D. Curb, A.R. Tall.
Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.
J Clin Invest, 97 (1996), pp. 2917-2923
[28.]
B. Agerholm-Larsen, B.G. Nordestgaard, R. Steffensen, G. Jensen, A. Tybjaerg-Hansen.
Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene.
Circulation, 101 (2000), pp. 1907-1912
[29.]
B. Agerholm-Larsen, A. Tybjaerg-Hansen, P. Schnohr, R. Steffensen, B.G. Nordestgaard.
Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study.
Circulation, 102 (2000), pp. 2197-2203
[30.]
A. Ritsch, H. Scharnagl, P. Eller, I. Tancevski, K. Duwensee, E. Demetz, et al.
Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study.
Circulation, 121 (2010), pp. 366-374
[31.]
S.E. Borggreve, H.L. Hillege, B.H. Wolffenbuttel, P.E. de Jong, M.W. Zuurman, G. van der Steege, et al.
An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study.
J Clin Endocrinol Metab, 91 (2006), pp. 3382-3388
[32.]
J.P. Corsetti, D. Ryan, D.L. Rainwater, A.J. Moss, W. Zareba, C.E. Sparks.
Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels.
Arterioscler Thromb Vasc Biol, 30 (2010), pp. 1657-1664
[33.]
E.A. Stein, E.M. Roth, J.M. Rhyne, T. Burgess, D. Kallend, J.G. Robinson.
Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.
Eur Heart J, 31 (2010), pp. 480-488
Copyright © 2012. Sociedad Colombiana de Cardiología y Cirugía Cardiovascular